2 results
Approved WMOCompleted
This study is designed to evaluate the immunogenicity and tolerability of V503 in young men, 16 to 26 years of age, in comparison to GARDASIL® in young men, 16 to 26 years of age. The safety and immunogenicity data will be used to bridge GARDASIL®…
Approved WMOCompleted
The purpose of this study is to determine the sustained benefit on safety and efficacy of AMG 334 compared to oral prophylactics in episodic migraine patients who have previously failed 1 to 2 prophylactic migraine treatments and therefore have a…